Items

PI: Yang E. Li, PhD

Investigation of both the genetic and epigenetic contributions to human diseases is a promising avenue of research. Our goal is to develop innovative computational tools/methods and utilize single-cell (epi)genomic techniques to gain a comprehensive understanding of gene regulation in mammalian models and human diseases, particularly in brain tumors and neuropsychiatric disorders.

PI: Tristan Qingyun Li, PhD

My lab is broadly interested in neuroimmunology with a focus on microglial biology. Particularly, we are interested in combining the cutting-edge single-cell genomic technology with in vitro and in vivo genetic, molecular and cellular tools to study microglial development, heterogeneity and mechanisms of neuro-immune interactions underlying brain structure and disease.

PI: Michael P. Meers, PhD

We study how different cell types in the human body are specified at the molecular level with three major themes. 1. Transcription factor-chromatin interactions 2. Cutting-edge genomics technology development 3. Chromatin dysregulation in disease

PI: Jeff Milbrandt, MD, PhD

Our laboratory studies the biological function of the GFL family of neurotrophic factors (GDNF, neurturin, persephin and artemin) that constitute the ligands for the Ret tyrosine kinase receptor, which is mutated in multiple endocrine neoplasia syndromes as well as thyroid cancers.

PI: Rob Mitra, PhD

The Mitra lab is interested in understanding how transcription factors achieve their in vivo specificities and dissecting the gene regulatory networks that govern developmental and disease processes. We are also interested in developing and applying methods for high throughput functional genomics.

• Gabor Egervari, MD, PhD | Egervari Lab
• Frederick Arnold, PhD | Arnold Lab
• Peter Jin, PhD | Jin Lab
• Joe Dougherty, PhD | Dougherty Lab
• Jeffrey Milbrandt, MD, PhD | Milbrandt Lab
• Tychele Turner, PhD | Turner Lab
• Guoyan Zhao, PhD | Zhao Lab
• Tristan Qingyun Li, PhD | Li Lab
• Yang (Eric) Li, PhD | Li Lab

We invite highly motivated candidates to apply for positions as postdoctoral fellows in the laboratory of Dr. Jeff Milbrandt in the Department of Genetics at Washington University in St. Louis. Our primary goal is to unravel the mechanism of axon degeneration and its role in neurodegenerative disease. Many of our projects are pursued collaboratively with the Aaron DiAntonio lab and focus on how defects in NAD homeostasis alter disease progression in peripheral neuropathy, ALS and retinal degenerative disorders.

The laboratories of Dr. Jeff Milbrandt and Dr. Rob Mitra invite highly motivated candidates to apply for positions as joint postdoctoral fellows in the Department of Genetics and McDonnell Genome Institute at WashU in St. Louis. These fellows will develop research programs in Personalized Medicine aimed at revealing the pathogenic mechanisms of disease-associated variants via monitoring phenotypic changes of genetically perturbed iPSC-derived neurons and glia.

The Ushiki Lab investigates the molecular mechanisms of cis-regulatory function and how noncoding genetic variation alters gene regulation in human disease. Our work integrates functional genomics, human genetics, and in vivo experimental systems to understand enhancer function across regulatory and phenotypic scales. We develop and apply both experimental and computational approaches, including in vivo Massively Parallel Reporter Assays (MPRAs), to define the sequence basis and functional consequences of enhancer activity and to expand MPRA-based approaches to other aspects of transcriptional regulation. Ongoing work in the lab is supported by an NHGRI K99/R00 award and the Preeclampsia Foundation’s Peter Joseph Pappas Research Grant.

The lab of Frederick Arnold is recruiting motivated individuals to apply for a Postdoc position on our team. Our research focuses on studying novel genetic risk factors and convergent disease mechanisms in neurodegenerative disorders. We are particularly focused on studying amyotrophic lateral sclerosis (ALS) and other diseases characterized by TDP-43 pathology.